Oxford Asset Management LLP Makes New $115,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR)

Oxford Asset Management LLP acquired a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 31,784 shares of the company’s stock, valued at approximately $115,000.

Several other institutional investors and hedge funds also recently bought and sold shares of ATYR. Federated Hermes Inc. purchased a new position in Atyr PHARMA during the fourth quarter worth $53,093,000. Tikvah Management LLC purchased a new position in Atyr PHARMA during the fourth quarter worth $8,908,000. Adage Capital Partners GP L.L.C. purchased a new position in Atyr PHARMA during the fourth quarter worth $3,620,000. Geode Capital Management LLC purchased a new position in Atyr PHARMA during the fourth quarter worth $3,229,000. Finally, Renaissance Technologies LLC purchased a new position in Atyr PHARMA during the fourth quarter worth $2,080,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on ATYR shares. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Friday, March 14th. Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an “overweight” rating for the company. Leerink Partners started coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 target price for the company. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $18.60.

Atyr PHARMA Stock Down 2.4 %

NASDAQ:ATYR opened at $3.27 on Tuesday. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66. The company has a 50-day moving average of $3.35 and a 200 day moving average of $3.38. The firm has a market cap of $290.57 million, a PE ratio of -3.48 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. As a group, research analysts anticipate that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.